IBDEI0L6 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10379,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,10379,1,5,0)
 ;;=5^Hx of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,10379,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,10380,0)
 ;;=V11.3^^67^675^25
 ;;^UTILITY(U,$J,358.3,10380,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10380,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,10380,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,10380,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,10381,0)
 ;;=V15.07^^67^675^26
 ;;^UTILITY(U,$J,358.3,10381,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10381,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,10381,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,10381,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,10382,0)
 ;;=V13.4^^67^675^27
 ;;^UTILITY(U,$J,358.3,10382,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10382,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,10382,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,10382,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,10383,0)
 ;;=V12.72^^67^675^31
 ;;^UTILITY(U,$J,358.3,10383,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10383,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,10383,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,10383,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,10384,0)
 ;;=V12.59^^67^675^30
 ;;^UTILITY(U,$J,358.3,10384,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10384,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,10384,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,10384,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,10385,0)
 ;;=V45.81^^67^675^29
 ;;^UTILITY(U,$J,358.3,10385,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10385,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,10385,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,10385,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,10386,0)
 ;;=V15.84^^67^675^28
 ;;^UTILITY(U,$J,358.3,10386,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10386,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,10386,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,10386,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,10387,0)
 ;;=V15.85^^67^675^47
 ;;^UTILITY(U,$J,358.3,10387,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10387,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,10387,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,10387,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,10388,0)
 ;;=V10.72^^67^675^34
 ;;^UTILITY(U,$J,358.3,10388,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10388,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,10388,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,10388,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,10389,0)
 ;;=V15.3^^67^675^35
 ;;^UTILITY(U,$J,358.3,10389,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10389,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,10389,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,10389,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,10390,0)
 ;;=V10.61^^67^675^37
 ;;^UTILITY(U,$J,358.3,10390,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10390,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,10390,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,10390,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,10391,0)
 ;;=V12.03^^67^675^39
 ;;^UTILITY(U,$J,358.3,10391,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10391,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,10391,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,10391,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,10392,0)
 ;;=V10.82^^67^675^40
 ;;^UTILITY(U,$J,358.3,10392,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10392,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,10392,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,10392,2)
 ;;=Hx of Malignant Melanoma^295240
